International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: unknown, P. 139194 - 139194
Published: Dec. 1, 2024
Language: Английский
International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: unknown, P. 139194 - 139194
Published: Dec. 1, 2024
Language: Английский
Advanced Therapeutics, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 18, 2024
Abstract Host‐directed therapies (HDTs) have emerged as a promising strategy to combat viral infections by modifying host factors and immune responses restrict replication improve patient outcomes. This review summarizes the latest advances future potential of HDTs in antiviral therapy. With developments genomics proteomics, new targets essential for been identified. Gene‐editing tools, such CRISPR‐Cas9, enable precise manipulation genes linked processes, paving way innovative HDTs. Emerging approaches, including RNA interference interference, further demonstrate specifically modify inhibit replication. Additionally, probiotics are being explored their capacity enhance modulate gut microbiota, offering natural safe method boosting defenses. Despite these advancements, significant challenges remain, particularly deciphering complex host–virus interactions ensuring safety efficacy therapies. Continued research clinical evaluation realize full provides comprehensive overview current HDT strategies, emphasizing promise shaping interventions.
Language: Английский
Citations
8Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: unknown, P. 189195 - 189195
Published: Oct. 1, 2024
Language: Английский
Citations
4Clinical Reviews in Allergy & Immunology, Journal Year: 2025, Volume and Issue: 68(1)
Published: Feb. 11, 2025
Language: Английский
Citations
0Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)
Published: Feb. 27, 2025
Recently, the use of antibody-drug conjugates (ADCs) in research and management solid tumors has increased, making them a key focus field oncology. In this study, we performed comprehensive literature review ADCs tumor treatment. We retrieved data from Web Science Core Collection (WoSCC). Following retrieval, conducted thorough bibliometric knowledge-mapping analysis collected articles. There was rapid growth number annual publications field. The United States had highest publication volumes led ADC for tumors. Additionally, Dana-Farber Cancer Institute output, G. Curigliano identified as most productive author. journal "Cancers" publishing on Furthermore, clustering terms such "breast cancer," "targeted therapy," "bladder "ovarian "expression," "drug delivery" emerged progressed. six themes by co-citation analysis, involving application four breast cancer, well design, mechanisms, strategies reducing cytotoxicity. At same time, based papers that have experienced citation burst recently, explored future development trends Overall, our inaugural provides systematic framework to guide studies Therefore, facilitating promoting further area.
Language: Английский
Citations
0Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 409 - 433
Published: Jan. 1, 2025
Language: Английский
Citations
0Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 319 - 335
Published: Jan. 1, 2025
Language: Английский
Citations
0Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: March 10, 2025
Neuroblastoma (NB) is a pediatric cancer that often manifests in high-risk form and characterized by frequent relapses resistance to conventional therapies. This underscores the urgent need for more effective targeted treatment strategies. One promising avenue has been identification of unique or overexpressed surface antigens on neoplastic cells, which facilitated development antibody conjugates related technologies. These include antibody-drug (ADCs) immunotoxins (ITs), deliver cytotoxic agents directly tumor as well antibody-fluorophore (AFCs), bind with high specificity target malignant tumors. Additionally, radioimmunotherapy (RIT) allows precise delivery radioactive isotopes linked monoclonal cells. ADCs, ITs, RIT represent novel class anti-cancer offering precision therapy reduced systemic toxicity, enabling longer potentially regimens. Meanwhile, AFCs are valuable tools diagnostics, aiding detecting characterizing tissues. Despite advancements NB, significant challenges persist, including optimizing payload delivery, mitigating off-target effects, addressing heterogeneity. Future research should also prioritize refining integrating these technologies into multimodal protocols improve outcomes NB patients.
Language: Английский
Citations
0Journal of Gynecologic Oncology, Journal Year: 2025, Volume and Issue: 36
Published: Jan. 1, 2025
Language: Английский
Citations
0Published: April 17, 2025
Language: Английский
Citations
0Journal of Ovarian Research, Journal Year: 2024, Volume and Issue: 17(1)
Published: Aug. 8, 2024
Ovarian cancer stands as the deadliest gynecologic malignancy, responsible for nearly 65% of all cancer-related deaths. The challenges in early detection and diagnosis, coupled with widespread intraperitoneal spread cells resistance to chemotherapy, contribute significantly high mortality rate this disease. Due absence specific symptoms lack effective screening methods, most ovarian cases are diagnosed at advanced stages. While chemotherapy is a common treatment, it often leads tumor recurrence, necessitating further interventions. In recent years, antibody-drug conjugates (ADCs) have emerged valuable tool targeted therapy. These complex biotherapeutics combine an antibody that specifically targets specific/associated antigen(s) potency anti-cancer drug through linker, offering promising approach treatment. identification molecular various human tumors has paved way development therapies, ADCs being forefront innovation. By delivering cytotoxic agents directly metastatic lesions, show potential managing chemo-resistant cancers. Mucins such MUC16, MUC13, MUC1 shown higher expression compared normal and/or benign samples, thus become ADC generation. traditional markers limited by their elevated levels non-cancerous conditions, mucins offer new possibility treatment cancer. This review comprehensively described generation therapy, highlighting importance quest improve outcome patients.
Language: Английский
Citations
2